placebo in patients who were overweight or obese and showed sustained, clinically relevant weight loss and improvement in lipid parameters
Therefore, we cannot directly conclude that the observed improvements in endocrine-metabolic profiles and oxidative stress in PCOS mouse ovaries following NAC intervention lead to enhanced fertility
This in turn leads to the induction of AP-1-dependent target genes, involved in cell proliferation, DNA repair, and cell death 27
Pain outcomes (WOMAC pain score): Additional findings: Systolic blood pressure reduced by 14 mmHg at 12 mg Improved non-HDL cholesterol, triglycerides, and hsCRP (a marker of inflammation) New safety signal -- dysesthesia: Dysesthesia (abnormal sensations such as burning, tingling, or numbness) emerged as a new adverse event in this trial: 8.8% at 9 mg 20.9% at 12 mg 0.7% at placebo TRIUMPH-5 -- Head-to-Head vs Tirzepatide TRIUMPH-5 is a Phase 3 head-to-head efficacy trial comparing retatrutide to tirzepatide in adults with obesity
Monitoring blood markers Routine laboratory testing is crucial for ensuring the medication is safe and effective and for identifying potential side effects early
v3.2.5 The BEST Tracker App For Your GLP Journey